Active Ingredient History

  • Now
Rimonabant (also known as SR141716; trade names Acomplia, Zimulti) is an anorectic antiobesity drug that was first approved in Europe in 2006 but was withdrawn worldwide in 2008 due to serious psychiatric side effects; it was never approved in the United States. Rimonabant is an inverse agonist for the cannabinoid receptor CB1 and was the first drug approved in that class.   Wikipedia

  • SMILES: Cc1c(nn(c2ccc(Cl)cc2Cl)c1c3ccc(Cl)cc3)C(=O)NN4CCCCC4
  • Mol. Mass: 463.8
  • ALogP: 5.94
  • ChEMBL Molecule:
More Chemistry
acomplia | n-(piperidin-1-yl)-5-(4-chlorophenyl)-1-(2,4-dichlorophenyl)-4-methyl-1h-pyrazole-3-carboxamide hydrochloride | rimonabant | sr-14171 | sr141716 | sr 141716 | sr-141716 | sr141716a | sr 141716a | sr-141716a | zimulti


Data collection and curation is an ongoing process for CDEK - if you notice any information here to be missing or incorrect, please let us know! When possible, please include a source URL (we verify all data prior to inclusion).

Report issue